Skip to Content
Morningstar
Get 14 Days Free

Alnylam Pharmaceuticals Inc ALNY

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

No-Moat Alnylam Reports Q1 Results Within Expectations; Maintaining Our $150 Fair Value Estimate

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

No-moat Alnylam Pharmaceuticals reported solid first-quarter results, bringing overall revenue to $178 million, driven by strong commercial execution of its RNA-based drugs. Product sales and pipeline development are tracking our expectations, and we are maintaining our $150 per share fair value estimate and no-moat rating for this developing firm.

Read Full Analysis

Company Profile

Business Description

Alnylam Pharmaceuticals Inc is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Contact
675 West Kendall Street, Henri A. Termeer Square
Cambridge, MA, 02142
T +1 617 551-8200
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 1,453

Related

Stock Strategist
Moderna's Innovation Still Building a Moat
The company's COVID-19 vaccine has shown the vast potential of its mRNA technology.
Karen Andersen
Fund Spy
An Excellent Choice for Broad Exposure to Healthcare
Gold-rated Vanguard Health Care benefits from an experienced manager.
Dan Culloton
Fund Spy
The Year in U.S. Equity Funds, 2019
A very good year for the market.
Nick Watson
Fund Spy
The Second Quarter in U.S. Stock Funds: Settling Down
After two volatile quarters, domestic stock funds took a breather.
David Kathman
Fund Times
A Superb Large Growth Fund For Your Watchlist
Managed by Morningstar's 2017 Domestic-Stock Fund Manager of the Year, Silver-rated Fidelity Growth Company has crushed its actively-managed competitors.
Katie Rushkewicz Reichart
US Videos
Wymer: Stock Market Pullback Possible This Year
Stock market fundamentals are healthy, but recent strong returns are unlikely to continue, says Fidelity Growth Company manager Steve Wymer, 2017 Domestic-Stock Fund Manager of the Year.
Katie Rushkewicz Reichart
Stock Analyst Update
Boosting Fair Value on Alnylam After Drug Trial
Based on the stellar results and clean safety profile, we think patisiran will likely receive approval in the U.S. and Europe in 2018, which drives our fair value change and peak sales estimates near $1 billion.
Kelsey Tsai
Stock Analyst Update
Alnylam's Prospects Today
Though we've lowered our fair-value estimate of the drugmaker after it announced that it has stopped development of a key drug, we still believe in the potential of Alnylam’s remaining pipeline.
Kelsey Tsai
Fund Times
Dodge & Cox Balanced Fund Isn't for Everyone
This Gold-rated fund is not a safe choice, but it's a strong one for the right kind of investor.
Laura Lallos
Stock Strategist
Competition Rising for Baxalta
The newly independent firm still has a narrow moat, however.
Karen Andersen
Market Update
Europe Tracks Asia Down
Gazala Parveen
Market Update
European Stocks Edge Up at Open
Gazala Parveen
US Videos
Will 'Knockout' Mice Make a Knockout Stock?
After a strong runup from our recommendation, is it time to take money off the table in Lexicon Pharmaceuticals?
Erik Kobayashi-Solomon
Stock Strategist
Betting on Biotech: The Mispriced and Fiscally Fit
These biotechs have the potential to provide a safe haven from market chaos.
Karen Andersen
Stock Strategist Industry Reports
Betting on Biotech: The Mispriced and Fiscally Fit
These biotechs have the potential to provide a safe haven from market chaos.
Karen Andersen
Quarter-End Insights
Our Outlook for the Health-Care Sector
Political winds could cast a cloud over health-care companies.
Debbie Wang